At enGene, we are at the vanguard of a new era in genetic medicine: Our novel gene delivery platform offers localized delivery of multiple gene cargos directly to mucosal tissues and other organs — potentially overcoming the limitations of viral-based gene therapies and advancing gene therapy beyond rare genetic diseases into the mainstream of clinical practice.

Detalimogene is a non-viral immunotherapy in development to treat non-muscle invasive bladder cancer (NMIBC), a disease with a significant patient burden, high clinical needs, and massive healthcare system economic impact.

Based on its preliminary efficacy and safety profile and ease of administration by urologists, we believe detalimogene can benefit patients across a wide variety of clinical settings.

Our breakthrough Dually Derivatized Oligochitosan® (DDX) platform opens possibilities for streamlining the use of genetic medicines in the treatment of serious diseases, especially diseases afflicting mucosal tissues.

The medicines we are developing are designed to transform mucosal cells into therapeutic production ‘factories’ that produce proteins and RNAs in the microenvironment of disease, creating a potent yet local therapeutic effect while avoiding the immunogenicity and systemic effects associated with viral-based genetic medicines.

Our scientists meticulously refined the DDX platform with a singular focus: to develop practical yet life-changing therapies for patients with underserved diseases. To advance our mission, we’ve assembled a team of industry leaders and innovators.

We are a team of passionate experts with extensive experience in drug development and commercialization across oncology, respiratory, and several other therapeutic areas.